<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Indium In-111 pentetreotide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Indium In-111 pentetreotide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Indium In-111 pentetreotide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="17077" href="/d/html/17077.html" rel="external">see "Indium In-111 pentetreotide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56619079"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Octreoscan</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56136937"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Octreoscan</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F13181732"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Radiopharmaceutical</li></ul></div>
<div class="block doa drugH1Div" id="F13182020"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="94b54c5b-04b9-4961-ac3d-48bfcfb56ab5">Neuroendocrine tumor imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroendocrine tumor imaging: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Planar imaging:</i>
<b>IV:</b> 3 mCi (111 MBq).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single photon emission computed tomograph (SPECT) imaging:</i>
<b>IV:</b> 6 mCi (222 MBq).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990532"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.</p></div>
<div class="block doha drugH1Div" id="F50987845"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F58509800"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F51344103"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="94b54c5b-04b9-4961-ac3d-48bfcfb56ab5">Neuroendocrine tumor imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Neuroendocrine tumor imaging:</b> IV: 0.14 mCi/kg (5 MBq/kg).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F56525956"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, flushing, hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hematocrit, decreased hemoglobin</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal transaminase</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, headache</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, asthenia</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F25595569"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;">There are no contraindications listed in the manufacturer’s labeling. </p></div>
<div class="block war drugH1Div" id="F13181803"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Glucose regulation: May cause severe hypoglycemia in patients with insulinomas; use with caution. Administer glucose before and during indium In-111 pentetreotide administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity, including rash, pruritus, and rarely anaphylaxis-related reactions and angioedema, have occurred; cases usually resolved without intervention or with symptomatic management.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Octreotide acetate: Sensitivity of scintigraphy may be reduced with concurrent octreotide; consider temporarily withdrawing octreotide prior to scintigraphy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and health care personnel. Use under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.</p></div>
<div class="block foc drugH1Div" id="F56619080"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Kit, [preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">Octreoscan:</p>
<p style="text-indent:-2em;margin-left:6em;">Injection, powder for reconstitution: Pentetreotide 10 mcg</p>
<p style="text-indent:-2em;margin-left:6em;">Injection, solution: Indium In-111 chloride 111 MBq (3.0 mCi) per 1 mL (1.1 mL)</p></div>
<div class="block dinfoc drugH1Div" id="F56136938"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Kit, [preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">Octreoscan:</p>
<p style="text-indent:-2em;margin-left:6em;">Injection, powder for reconstitution: Pentetreotide 10 mcg</p>
<p style="text-indent:-2em;margin-left:6em;">Injection, solution: Indium In-111 chloride 111 MBq (3.0 mCi) per 1 mL (1.1 mL)</p></div>
<div class="block adm drugH1Div" id="F13191456"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> For IV administration. Patient should be well-hydrated before and after administration. To minimize bladder exposure, patients should increase fluid intake and void frequently for 24 hours post administration. Laxatives should be used before and for 48 hours after receiving indium In-111 pentetreotide.</p>
<p style="text-indent:0em;margin-top:2em;">Radiopharmaceutical; use appropriate precautions for handling and disposal.</p></div>
<div class="block admp drugH1Div" id="F52614175"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Radiopharmaceutical; use appropriate precautions for handling and disposal. When handling and administering, follow appropriate safety measures to minimize radiation exposure during administration; use waterproof gloves and effective shielding, including syringe shields.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: For IV administration only. May be administered undiluted or diluted with NS prior to administration. Patient should be well-hydrated before and after administration. To minimize bladder exposure, patients should increase fluid intake and void frequently for 24 hours post administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11438641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11438641'])">Ref</a></span>). Laxatives should be used before and for 48 hours after receiving indium In-111 pentetreotide.</p></div>
<div class="block use drugH1Div" id="F13181733"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroendocrine tumor imaging:</b> Scintigraphic localization of primary and metastatic neuroendocrine tumors with somatostatin receptors</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Due to greater sensitivity and decreased radiation dose, imaging agents targeting somatostatin receptors labeled with Gallium 68 (eg, Gallium Ga 68 Dotatate) are preferred over somatostatin receptor scintigraphy (Indium In-111 Pentetreotide) (Hope 2018; Sadowski 2016).</p></div>
<div class="block mst drugH1Div" id="F13255252"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>
</div>
</div>
<div class="block pri drugH1Div" id="F13181959"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Animal studies have not been conducted. Radiopharmaceuticals have the potential to cause fetal harm. Use during pregnancy only if clearly needed.</p></div>
<div class="block brc drugH1Div" id="F13182003"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">In one patient report, only 0.025% of the administered dose was excreted in breast milk, which would have resulted in an infant dose of 82 mrem (0.82 mSv) if breast-feeding had not been interrupted. This amount is so low that interruption of breast-feeding is not necessary; however, the radiation exposure to the infant from the mother while being held in close contact may be sufficiently high that interruption of breast-feeding may be recommended in order to limit the time of close contact (Rubow 2000).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F51192192"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Octreoscan</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Octreoscan</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Octreoscan</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Octreoscan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Octreoscan</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Octreoscan</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Octreotide, 111In</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11438641">
<a name="11438641"></a>Balon HR, Goldsmith SJ, Siegel BA, et al, "Society of nuclear Medicine Procedure Guideline for Somatostatin Receptor Scintigraphy with IN-111 Pentetreotide," J Nucl Med, 2001, 42(7):1134-8. Available at http://interactive.snm.org/docs/pg_ch27_0403.pdf. Last accessed April 27, 2010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/indium-in-111-pentetreotide-drug-information/abstract-text/11438641/pubmed" id="11438641" target="_blank">11438641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29025982">
<a name="29025982"></a>Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. <i>J Nucl Med</i>. 2018;59(1):66-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/indium-in-111-pentetreotide-drug-information/abstract-text/29025982/pubmed" id="29025982" target="_blank">29025982</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  OctreoScan (indium In-111 pentetreotide) [prescribing information]. Maryland Heights, MO: Curium US LLC; February 2022.</div>
</li>
<li>
<div class="reference">
                  Rubow SM and Ellman A, "Indium-111 Scintigraphy and Breastfeeding," <i>Eur J Nucl Med</i>, 2000, 27(8):1057.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26712231">
<a name="26712231"></a>Sadowski SM, Neychev V, Millo C, et al. Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. <i>J Clin Oncol</i>. 2016;34(6):588-596.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/indium-in-111-pentetreotide-drug-information/abstract-text/26712231/pubmed" id="26712231" target="_blank">26712231</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16797 Version 85.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
